Duopharma Biotech Bhd Asset Resilience Ratio

Latest as of December 2025: 20.08%

Duopharma Biotech Bhd asset resilience ratio. Duopharma Biotech Bhd (7148) has an Asset Resilience Ratio of 20.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Duopharma Biotech Bhd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

RM290.87 Million
≈ $73.03 Million USD Cash + Short-term Investments

Total Assets

RM1.45 Billion
≈ $363.62 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Duopharma Biotech Bhd (2016–2024)

Asset resilience ratio of Duopharma Biotech Bhd from 2016 to 2024. This chart shows how Duopharma Biotech Bhd's Asset Resilience Ratio has changed over time. Read Duopharma Biotech Bhd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Duopharma Biotech Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 7148 current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents RM290.87 Million 20.08%
Short-term Investments RM0.00 0%
Total Liquid Assets RM290.87 Million 20.08%

Asset Resilience Insights

  • Good Liquidity Position: Duopharma Biotech Bhd maintains a healthy 20.08% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Duopharma Biotech Bhd Industry Peers by Asset Resilience Ratio

Compare Duopharma Biotech Bhd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Galderma Group N
SW:GALD
Drug Manufacturers - Specialty & Generic 3.56%
Enzymatica publ AB
ST:ENZY
Drug Manufacturers - Specialty & Generic 22.17%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 9.04%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%

Duopharma Biotech Bhd Asset Resilience Ratio by Year (2016–2024)

Duopharma Biotech Bhd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Duopharma Biotech Bhd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 11.71% RM161.25 Million
≈ $40.48 Million
RM1.38 Billion
≈ $345.72 Million
-12.35pp
2023-12-31 24.06% RM323.59 Million
≈ $81.24 Million
RM1.35 Billion
≈ $337.72 Million
+17.71pp
2022-12-31 6.34% RM77.49 Million
≈ $19.46 Million
RM1.22 Billion
≈ $306.78 Million
+3.73pp
2021-12-31 2.62% RM30.45 Million
≈ $7.64 Million
RM1.16 Billion
≈ $292.27 Million
-2.37pp
2020-12-31 4.99% RM52.81 Million
≈ $13.26 Million
RM1.06 Billion
≈ $265.74 Million
+0.46pp
2019-12-31 4.53% RM41.67 Million
≈ $10.46 Million
RM919.80 Million
≈ $230.93 Million
+1.94pp
2018-12-31 2.59% RM21.70 Million
≈ $5.45 Million
RM836.38 Million
≈ $209.99 Million
-4.33pp
2017-12-31 6.93% RM48.86 Million
≈ $12.27 Million
RM705.24 Million
≈ $177.06 Million
-5.84pp
2016-12-31 12.77% RM84.48 Million
≈ $21.21 Million
RM661.46 Million
≈ $166.07 Million
--
pp = percentage points

About Duopharma Biotech Bhd

KLSE:7148 Malaysia Drug Manufacturers - Specialty & Generic
Market Cap
$268.08 Million
RM1.07 Billion MYR
Market Cap Rank
#15067 Global
#179 in Malaysia
Share Price
RM1.11
Change (1 day)
-0.89%
52-Week Range
RM1.08 - RM1.55
All Time High
RM2.86
About

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more